 |
|
|
 |
Scientists Find That Heart Muscle Cells Regenerate After A Heart Attack
Challenging one of medicine's long-standing beliefs, a team of scientists funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Aging (NIA) has found the strongest evidence to date that human heart muscle cells regenerate after a heart attack. In a paper published in the June 7 issue of the New England Journal of Medicine, scientists from New York Medical College in Valhalla, NY report their success in finding large scale replication of heart muscle cells in two regions of the heart, and in identifying several other key indicators of cell regeneration. more
|
|
Gene Therapy May Hold Key To Treatment And Cure Of Hemophilia Complications
The National Hemophilia Foundation is delighted by the promising results from a nonviral gene therapy-based treatment for severe hemophilia A (factor VIII deficiency). The study, led by researchers at Beth Israel Deaconess Medical Center utilizing a nonviral gene therapy developed by Transkaryotic Therapies (TKT), showed the treatment, which used patients' own cells, may be effective in reducing the occurrence of spontaneous bleeding, a frequent and potentially lethal symptom of the disorder. The findings are published in the 07 June 2001, issue of the New England Journal of Medicine. more
|
|
|
|
Investigational Biologic Infliximab Of 'High' Clinical Benefit In Psoriasis
The investigational drug infliximab may provide a rapid and high degree of clinical benefit in patients with moderate- to-severe psoriasis, according to research published by the University of Medicine and Dentistry of New Jersey (UMDNJ) in the 09 June 2001, issue of The Lancet. Approximately a quarter of the seven million Americans with psoriasis suffer from moderate- to-severe disease, which can be both physically and emotionally debilitating. more
|
|
Casodex (Bicalutamide) May Reduce Risk Of Disease Progression In Men With Early Prostate Cancer
In data presented from the largest prostate cancer clinical trial program in the world, Casodex ® 150 mg was shown to significantly reduce (42 percent) the risk of disease progression in men with localized or locally advanced prostate cancer compared to placebo. The program was undertaken to study the effect of Casodex 150 mg as an immediate or adjuvant treatment for early prostate cancer and was designed on the same premise as the adjuvant trials of tamoxifen in breast cancer. more
|
|
Enzyme Therapy Shown Effective And Safe For Fabry Disease
Enzyme replacement therapy effectively and safely reduces neuropathic pain in patients with Fabry disease, results of a double-blind placebo-controlled clinical trial show. The therapy also corrects the underlying metabolic defect in patients' cells and improves their heart and kidney functions. This is the first published report to show significant clinical benefits from a controlled study of enzyme replacement therapy for Fabry disease. The study appeared in the 06-June-2001, issue of JAMA. Information for patients can also be found with this article, courtesy of the National Institute of Neurological Disorders And Stroke. more
|
|
|
